Pulmonary Rehabilitation and Self-esteem in Patients With COPD (ESMOI)

January 26, 2021 updated by: University Hospital, Brest

Effects of Pulmonary Rehabilitation on Self-esteem in Patients With COPD

the aim of this study is to evaluate the evolution of self-esteem during a pulmonary rehabilitation program, in COPD patients.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

76

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Brest, France, 29609
        • CHRU de Brest
      • Morlaix, France, 29672
        • CH Pays de Morlaix

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

COPD patients admitted to a pulmonary rehabilitation program

Description

Inclusion Criteria:

  • Patient with stage 2 to 4 (A to D) COPD admitted to a pulmonary rehabilitation program
  • Patient aged 18 or over
  • Patient able to consent and having signed a consent form

Exclusion Criteria:

  • Patient with pain, osteoarthritis or shoulder surgery
  • Patient with a history of Pneumonectomy, lobectomy less than 6 months old
  • Refusal of participation
  • Patient with an inability to complete a pulmonary rehabilitation program in totality
  • Pregnant or breast-feeding women
  • Patient under tutorship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PSI-6
Time Frame: PSI-6 is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)
the physical self inventory- 6 (PSI-6) allows to evaluate self esteem
PSI-6 is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
6MWT
Time Frame: the 6MWT is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)
The 6-minute walk test allows to evaluate exercise capacity
the 6MWT is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)
HAD
Time Frame: HAD is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)
the hospital anxiety and depressive scale (HAD) measure the anxiety and depression
HAD is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)
SGRQ
Time Frame: SGRQ is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)
the Saint-George respiratory Questionnaire (SGRQ) measure the quality of life
SGRQ is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
MMRC
Time Frame: MMRC is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)
The modified medical research Council dyspnea scale measure dyspnea
MMRC is measured at the biginning and at the end of the pulmonary rehabilitation program (4 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 17, 2019

Primary Completion (Actual)

September 29, 2020

Study Completion (Actual)

September 29, 2020

Study Registration Dates

First Submitted

November 13, 2019

First Submitted That Met QC Criteria

November 20, 2019

First Posted (Actual)

November 21, 2019

Study Record Updates

Last Update Posted (Actual)

January 27, 2021

Last Update Submitted That Met QC Criteria

January 26, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • ESMOI (29BRC19.0225)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected data that underlie results in a publication

IPD Sharing Time Frame

Data will be available beginning one year and ending five years following the publication

IPD Sharing Access Criteria

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

3
Subscribe